



HAL
open science

The blood platelets contribution to innate host defense - what they have learned from their big brothers

Matthias Klinger

► **To cite this version:**

Matthias Klinger. The blood platelets contribution to innate host defense - what they have learned from their big brothers. *Biotechnology Journal*, 2009, 4 (6), pp.914. 10.1002/biot.200800362 . hal-00490110

HAL Id: hal-00490110

<https://hal.science/hal-00490110>

Submitted on 8 Jun 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



**The blood platelets contribution to innate host defense -
what they have learned from their big brothers**

Journal:	<i>Biotechnology Journal</i>
Manuscript ID:	biot.200800362.R1
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	01-May-2009
Complete List of Authors:	Klinger, Matthias; University of Lübeck, Institute of Anatomy
Keywords:	blood platelets, innate immunity, blood plasma, thrombin, reactive oxygen species



view

1
2
3 **Research Article ((8450 words))**
4

5 **The blood platelets contribution to innate host defense – what they have learned from**
6
7 **their big brothers**
8
9

10
11
12 Dorit M.W. Zander and Matthias H. F. Klinger
13
14
15
16
17
18
19
20
21

22 **Keywords:** blood platelets, thrombin, reactive oxygen species, plasma, innate immunity
23
24
25
26
27

28 Dr. Matthias Klinger
29

30 Institute of Anatomy
31

32 Center of Structural and Cell Biology in Medicine
33

34 University of Lübeck
35

36 Ratzeburger Allee 160
37

38 D-23538 Lübeck
39
40
41
42

43 phone: 0049 / 451 / 500 4013
44

45 email: klinger@anat.uni-luebeck.de
46
47
48
49
50
51
52
53
54
55

56 **Abbreviations:**
57

58 BC - buffy coat; DPI - Diphenylene iodonium chloride; NADP - Nicotinamide adenine
59 dinucleotide phosphate; OCS - open canalicular system; PAR - protease activated receptor;
60 PC - platelet concentrate; PMA - Phorbol 12-myristate 13-acetate; ROS - reactive oxygen
species

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Abstract

Bactericidal effects of blood platelets have been known for more than 120 years, but the underlying mechanisms are largely obscure. Keeping in mind structural and functional analogies of platelets to neutrophils, three different mechanisms are thinkable: Engulfment of pathogens, release of microbicidal proteins, and production of reactive oxygen species (ROS). Here, we focus on the release of ROS and a possible contribution of blood plasma and thrombin to the bactericidal effects.

Killing of bacteria was evaluated by DNA fluorescence labeling and electron microscopy.

Release of ROS by platelets was measured photometrically by cytochrome C and phenolred/peroxidase assays and was further evaluated by topological methods.

We found that (1) platelets produce 1500 times less O_2^- and 4000 times less H_2O_2 compared to neutrophils, (2) ROS do not effect the killing rates, (3) no local enrichment of ROS was detectable. On the other hand, thrombin and plasma proteins with a MW >100 kDa are essential for bactericidal effects.

We suggest that platelets contribute to the innate host defence by providing a catalytical surface for synthesis of thrombin. In the presence of a heat-instable plasma protein, thrombin may generate a strong bactericidal complex, which is only effective in close vicinity to the platelet membrane.

Introduction

Platelets are primarily known for their crucial role in haemostatic processes but they do have far more functions. They play a role in inflammation by quickly reacting to various specific signals and releasing inflammatory mediators [1]. They modulate vascular reactions, release mediators for chemotaxis and stimulation of leukocytes, and participate in wound repair by release of PDGF, Angiopoietin or EGF [1]. In this way, platelets chip into all stages of inflammation.

Inflammation is often the consequence of invading pathogens, and it seems to be logical that platelets participate in antimicrobial host defense as they are the first cellular elements in the blood that accumulate at any site of a vascular lesion [2-4]. Various bacteria bind to platelets [5-7] and are embedded and killed in platelet aggregates [8;9]. The binding of bacteria can be a direct one via receptors or can be indirect via a bridging molecule like fibrinogen [10].

Although a bactericidal function of platelets has been described for more than 120 years now, the underlying mechanisms are not clear [11]. Analogous to neutrophils, there are 3 potential killing mechanisms that may be proposed to operate in platelets: 1. platelets store and process bactericidal peptides, 2. they have a phagocytic capacity, and 3. they synthesize reactive oxygen species (ROS). As summarized below, mechanisms 1 and 2 have been under intensive investigation for longer times, but the possible role of ROS in killing bacteria by platelets has not been studied so far and stimulated the present study.

In 1972 Nachman and Weksler detected bactericidal peptides in platelet granules [4]. They were identified and described in detail in rabbits by Yeaman et al.[12] and later on in humans by Krijgsveld et al.[13] and Tang et al.[14]. But Tang et al. reported about conflicting data on bactericidal activities of purified peptides, possibly due to inhibitory effects of sodium phosphate [14], which is also used in our experiments. Moreover, Krijgsveld et al.[13] needed 100-fold higher platelet concentrations to extract thrombocidins in bactericidal amounts than we used in our killing model. Therefore we asked if additional mechanisms exist that are responsible for the observed strong killing effects and one of them could be phagocytosis. Platelets show three main phagocytic features that are typical for leucocytes [4;15]: they interact with particulate material, they contain lysosomes in the cytoplasm and they store inflammatory mediators. But true phagocytosis of bacteria, which means that the vacuoles have no permanent contact to the extracellular space, is not established in platelets yet. Platelets enclose bacteria trapped within an aggregate or act as “covercytes” by covering the bacterial surface [16]. They also may take up bacteria into the open canalicular system [3;16].

1
2
3 White [16] concluded that bacteria-platelet interaction occurs spontaneously after prolonged
4 incubation times or prestimulation of platelets. Since enclosing by platelets does not seem to
5 alter bacteria morphologically, it is questionable if this mechanism of ingestion is bactericidal.
6
7 And finally, platelets could have the possibility to kill bacteria by synthesis of ROS [17-24],
8 which act as potent killing agents with particularly high efficacy in leukocytes [25]. In this
9 way, neutrophils and macrophages increase oxygen consumption during phagocytosis in what
10 has been termed respiratory burst [26]. It was observed that ROS production in neutrophils
11 and osteoclasts may be locally restricted to areas of "ruffled membranes" [27;28]. Since we
12 found these ruffled membranes also in platelets, especially at platelet-bacteria binding sites
13 [9], we assumed that platelets could kill bacteria by the local release of ROS. Keeping in mind
14 the analogies to neutrophils, we always investigated the ROS release by platelets and
15 neutrophils simultaneously, taking the latter "big brothers" as the positive control.
16
17 Thus, we asked if ROS production in platelets is high enough to kill bacteria in general and if
18 not so, if locally restricted ROS release might explain the observed killing effects. Since the
19 amount of ROS released by platelets was not sufficient alone to explain the bactericidal
20 effects, we further investigated the role of plasma proteins and the effect of thrombin in the
21 observed killing model.
22

23
24 We tested the killing potential of gel-filtered platelets (plasma-free) in buffer and determined
25 the killing rates after adding increasing plasma portions, furthermore after addition of heat-
26 inactivated plasma and after the addition of high (> 100 kDa) and low (<100 kDa) molecular
27 weight plasma protein fractions.
28

29
30 Thrombin performs its platelet stimulation in humans via the protease activating receptors
31 (PAR) 1 and 4 on the platelet surface [29;30] but also cleaves plasma proteins to generate
32 fibrin [31].
33

34
35 Because the addition of thrombin was crucial to get bactericidal effects, we dissected the
36 action of thrombin by selecting the stimulation of the protease activating receptors (PAR) 1
37 and 4 on the platelet surface. We activated PAR 1 with the synthetic thrombin receptor
38 agonist SFLLRN [32] and the PAR 4 with GYPGKF [33], and determined the killing rates.
39
40 Furthermore, we mimicked the proteolytical function of thrombin by the addition of trypsin,
41
42 **we inhibited thrombin activity by hirudin**, and compared all killing rates.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Materials and Methods

Platelet and neutrophil preparation

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Buffy coats (BC) or platelet concentrates (PC) were collected from healthy donors after informed consent and were kindly provided by Dr. Peter Schlenke from the Department of Immunology and Blood Transfusion, University of Luebeck.

For photometric assays and fluorescence microscopy, BC were prepared by centrifugation (Optipac PL-146/Optipress, Baxter). Platelet-rich plasma was isolated by centrifugation of BC for 15 min at 160 x g and was allowed to rest for 20 min to recover from the trauma of centrifugation and compaction. PC were then obtained by centrifugation of platelet-rich plasma for 10 min at 1000 x g. Platelets were resuspended in Tyrode buffer, containing 138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO₃, 5 mM HEPES, 0.4 mM Na₂HPO₄, 1 mM MgCl₂ and 5 mM glucose [19]. The number of contaminating leukocytes was < 0.1 %.

Neutrophils were separated from other cells in the BC using a Histopaque1077[®] gradient centrifugation (Sigma, Schnellendorf, Germany) for 30 min at 400 x g followed by a subsequent ammonium chloride haemolysis [34]. Neutrophils were resuspended in RPMI 1640[®] medium (Sigma) and were counted in a Neubauer chamber.

For Killing assays, PC were prepared by plateletpheresis (Amicus[®] cell separator, Baxter). Platelet counts were adjusted to 6x10⁸/ml. PC were stored for a maximum of 3 days at 22°C under constant agitation for better gas exchange and prevention of clumping.

Gel-filtered platelets were obtained by spinning down PC for 12 min at 1200 x g onto a 50 % albumin cushion [35]. Platelets were collected and resuspended in HEPES buffer containing 0.35 % BSA, 137 mM NaCl, 2.7 mM KCl, 3 mM Na₂HPO₄, 1 mM MgCl₂, 5.5 mM glucose and 3.5 mM HEPES and then applied to a Sepharose 2B column (Sigma).

Bacteria suspensions

Bacillus subtilis (*B. subtilis*), *Escherichia coli* (*E. coli*) and *Staphylococcus aureus* (*S. aureus*) were grown on tryptone-soya agar plates (Oxoid, Wesel, Germany) at 37°C for 16 h. For killing experiments, bacteria were collected and suspended in 0.9 % sodium chloride to 10⁹ bacteria/ml.

Plasma preparation and fractionation

Human plasma was obtained by centrifugation of PC for 90 sec at 14 000 x g. To prepare heat-inactivated plasma, the obtained plasma were incubated for 20 min at 56°C. To

1
2
3 fractionate the plasma proteins, the plasma were centrifuged through a Microcon[®] filter
4 (Millipore) YM-10 for 30 min at 14 000 g x and YM-100 for 12 min at 14 000 x g. We got 4
5 plasma protein fractions: < 10 kDa, > 10 kDa, < 100 kDa and > 100 kDa.
6
7
8
9

10 **Serum preparation**

11 Whole blood without any anticoagulants was allowed to clot until retraction of the fibrin clot.
12 After 30 min at 20 °C, the samples were centrifuged for 10 min at 3000 x g and the
13 supernatant was collected.
14
15
16
17

18 **Platelet stimulation and inhibition**

19 To achieve maximum killing rates, platelets were stimulated with thrombin (Sigma) at a
20 concentration of 2 U/ml for 10 min at 37°C. **Inhibition of thrombin was performed by hirudin**
21 **(Sigma) at a concentration of 5 antithrombin units/ml.**
22
23
24
25

26 To stimulate the NAD(P)H-oxidase, we used phorbol myristate acetate (PMA, Sigma) at
27 concentrations up to 1 µM. To block the NAD(P)H-oxidase, we used the unspecific
28 NAD(P)H-oxidase inhibitor Diphenylene iodonium chloride (DPI; Sigma, 50-500 nM). Cells
29 were preincubated with DPI for 30 min before any stimulation, and DPI was also present in
30 the incubation medium.
31
32
33
34

35 For selective stimulation of the thrombin receptors, we stimulated PAR 1 with SFLLRN (SF,
36 Sigma, 75 µM) and PAR 4 with GYPGKF (GYP, Sigma, 750 µM). To mimic a proteolytical
37 action of thrombin, we used trypsin (Sigma, 64 000 U/ml).
38
39
40
41

42 **Superoxide assay**

43 The superoxide (O₂⁻) production was measured by the reduction of cytochrom C as described
44 by Krötz et al. [19]. Platelets were stimulated with PMA and thrombin or inhibited by DPI.
45 After incubation times of 15 min (neutrophils) or 30 min (platelets) at 37°C, the absorbance of
46 the supernatants was measured with the spectrometer (Spectronic 20 Genesis) at 550 nm. The
47 O₂⁻ dependent part of cytochrome C reduction was calculated from the absorbance difference
48 between samples with or without addition of superoxide dismutase (SOD, 380 U/ml). The
49 tests were performed in triplicates. The data were translated into nanomole (nM) of O₂⁻ using
50 the extinction coefficient of $E_{550\text{nm}} = 29.5 \text{ mM}^{-1} \times \text{cm}^{-1}$.
51
52
53
54
55
56
57
58
59
60

Hydrogen peroxide assay

1
2
3 The rate of hydrogen peroxide (H_2O_2) production was detected by the peroxidase/phenolred
4 assay as described by Cabanis et al. [34]. Cells were incubated for 30 min (neutrophils) or
5 45 min (platelets) at 37°C in the presence of 17 U/ml horseradish-peroxidase (Sigma) and
6 0.2 mg/ml phenolred in buffer. After addition of NaOH the absorbance in the supernatant was
7 measured at 610 nm. The tests were performed in triplicate. Concentrations of H_2O_2 were
8 calculated by means of a standard curve ranging till $0.6 \mu\text{mol/l}$. To additionally detect
9 released O_2^- , we applied superoxide dismutase (SOD), which catalyzes the conversion of O_2^-
10 into H_2O_2 .
11
12
13
14
15
16
17
18

19 **Topological detection of H_2O_2 by fluorescence microscopy**

20 Cells were dropped on prewarmed slides to adhere. After washing with phosphate buffered
21 saline (PBS), $10 \mu\text{M}$ of the fluorescence dye Oxyburst Green $\text{H}_2\text{HFF}^\circledR$ (Molecular Probes,
22 Eugene, Oregon) was added. Cells were stimulated by $0.5 \mu\text{M}$ of PMA (Sigma), 160 mg/l
23 horseradish-peroxidase were added, and samples were incubated for 30 min. Samples were
24 washed with PBS and were imaged using the confocal laser scanning microscope (LSM 510
25 Meta, Zeiss, Jena, Germany). The microscope was operated at 488 nm excitation, and a 510-
26 580 nm emission filter was used.
27
28
29
30
31
32
33
34

35 **Topological detection of H_2O_2 by electron microscopy**

36 Cerium chloride reacts with H_2O_2 to form ceriumperhydroxide, which precipitates in the form
37 of electron dense crystals at the side of H_2O_2 synthesis [36]. Neutrophils or platelets were
38 incubated on Thermanox[®] Plastic Coverslips (Nunc, Wiesbaden, Germany) for 30 min in the
39 presence of cerium chloride (CeCl_3 , 10 mM, Sigma), with or without $1 \mu\text{M}$ PMA and *B.*
40 *subtilis*. Cells were diluted in ringer lactate solution (Fresenius, Bad Homburg, Germany)
41 with addition of 5 mM glucose according to Telek et al. [37]. Samples were fixed with 2.5 %
42 glutaraldehyde for 2 h and were washed in 0.1 M cacodylate puffer, pH 7.2. Postfixation was
43 performed with 1 % osmiumtetroxide (OsO_4). Samples were dehydrated in ethanol and
44 embedded in araldite (Fluka, Buchs, Switzerland). Ultrathin sections were stained with uranyl
45 acetate and lead citrate and were viewed with a Philips EM 400.
46
47
48
49
50
51
52
53
54
55

56 **Killing assays**

57 For quantitative detection of dead bacteria, we used DNA double labelling with the
58 fluorescence dye LIVE/DEAD[®] BacLight[™] (Molecular Probes, Eugene, USA). The rate of
59
60

1
2
3 dead bacteria was calculated by dividing the number of red stained bacteria by the sum of red
4 and green stained bacteria and was expressed as % killing.

5
6 For killing assays, platelets were mixed with *B. subtilis* in a ratio of 1:1. After addition of
7 stimulators or inhibitors (thrombin, PMA, DPI), samples were incubated on glass slides for
8 10 up to 45 min. Cells were labelled with LIVE/DEAD® and were imaged using the
9 fluorescence microscope (Axiophot®, Zeiss, Oberkochen, Germany) at 630 x magnifications
10 for every sample. Three optical fields containing a continuous layer of platelets were chosen.
11 300 bacteria were counted with respect to their labels. Baseline percentages of dead bacteria
12 were determined by LIVE/DEAD® labelling of *B. subtilis* after suspension in sodium
13 chloride without any additives. Maximum controls were performed by 10 min coincubation of
14 LIVE/DEAD®-labelled *B. subtilis* and thrombin-stimulated platelets (2 U/ml).
15
16

17
18
19
20
21
22
23 The validity of the LIVE/DEAD® staining method was proven by the conventional colony
24 counting method: mixed bacteria suspensions with 0, 25, 50, 75 and 100 % of dead bacteria
25 were checked both by manual counting following LIVE/DEAD® staining and by counting of
26 the colony forming units (CFU) after plating bacteria on agar and incubation for 24 h at 37°C.
27
28 In agreement with the LIVE/DEAD® data sheet, we found an excellent correlation between
29 growing on agar plates and LIVE/DEAD® staining.
30
31
32

33 To appraise the direct hurtful effect of H₂O₂ on *B. subtilis* we developed an automated
34 method. Killing of bacteria was achieved by adding increasing concentrations of H₂O₂.
35 96-well microtiter plates were loaded with 50 µl of bacteria suspension and H₂O₂ in
36 concentration between 50 µM to 50 mM. After 10 min incubation time, bacteria were labelled
37 with 5 µM LIVE/DEAD® and killing was determined by measuring the emitted fluorescence
38 signal with the LSM 510 Meta.
39
40
41
42

43 Three images per well were recorded using the multitrack mode. Numbers of green and red
44 pixels between intensities 50- 255 were counted automatically. We calculated the killing rates
45 by dividing the number of red pixels by the sum of red and green pixels. Double coloured
46 pixels (colocalised) were excluded.
47
48
49
50
51

52 53 **Statistics**

54 All data are expressed as mean ± standard deviation (SD). Statistical significance (p<0.05)
55 was determined by using the Wilcoxon rank sum test performed by JMP® software (SAS
56 Institute) and was characterized at the figures by an asterisk (*).
57
58
59
60

Results

Killing rates of *B. subtilis*, *E. coli* and *S. aureus* diverge

Thrombin-stimulated platelets in plasma are capable to kill *B. subtilis* and *E. coli* up to 97 %, but were not able to kill *S. aureus*. All following killing tests were performed with the most susceptible bacteria, *B. subtilis*, which also yielded the brightest fluorescence labeling.

O₂⁻ production in platelets is very low compared to neutrophils

To see if platelets release ROS in bactericidal amounts, we first investigated the O₂⁻ release photometrically. Platelets produce a small and hardly detectable amount of superoxide.

Resting platelets show a basal production of $0.2 \pm 0.27 \mu\text{M O}_2^- / \text{min} / 7 \times 10^8$ platelets (n=9).

Stimulation with 1 μM PMA led to a 2.4-fold increase of O₂⁻ release on average ($0.47 \pm 0.46 \mu\text{M O}_2^-$). Thrombin (2 U/ml) led to an even lower increase of O₂⁻ production up to 1.5-fold, again in only some preparations ($0.33 \pm 0.14 \mu\text{M O}_2^-$, n=5).

In general, no stimulators were able to induce platelet O₂⁻ formation significantly, since platelets of some donors did not respond. If platelet stimulation with PMA was performed in the presence of the unspecific NAD(P)H-oxidase inhibitor DPI, we observed a tendency of decreasing O₂⁻ production from $0.47 \pm 0.46 \mu\text{M}$ to $0.34 \pm 0.51 \mu\text{M O}_2^-$.

In contrast, neutrophils strongly respond to PMA. One neutrophil produced about 1500-fold more O₂⁻ after PMA stimulation compared to one platelet. By addition of DPI, the maximum O₂⁻ release was reduced from $1.58 \pm 0.17 \mu\text{M O}_2^- / \text{min} / 10^6$ neutrophils to $0.66 \pm 0.08 \mu\text{M}$ (p<0,001, Wilcoxon, n=5). Thrombin had no effect on neutrophils (Fig.1).

Low H₂O₂-formation in platelets in contrast to neutrophils

O₂⁻ is unstable and has a short half live time in the millisecond range. It is converted into H₂O₂, which is detectable with the phenolred/peroxidase assay. Resting platelets produce $80 \pm 50 \text{ nM H}_2\text{O}_2 / \text{min} / 10^9$ platelets (n=5). Following stimulation with 1 μM PMA, platelets release significantly more H₂O₂ ($115 \pm 30 \text{ nM H}_2\text{O}_2$, p= 0.03, Wilcoxon). Addition of DPI holds the H₂O₂ basal release to $64 \pm 41 \text{ nM}$. SOD converts generated O₂⁻ into H₂O₂. Thus the addition of SOD in this assay can detect indirectly the O₂⁻ release, too. In the presence of SOD, PMA stimulation fails to further enhance the H₂O₂ production (Fig. 2) These findings correspond to the low detection of O₂⁻ in the cytochrome C assay (Fig. 1).

In contrast to platelets, neutrophils produce about 4000-fold more H₂O₂ on a single cell basis. 1 μM PMA increases the H₂O₂ production from $134 \pm 36 \text{ nM H}_2\text{O}_2 / \text{min} / 10^5$ neutrophils up to $219 \pm 22 \text{ nM}$ (p<0.001, Wilcoxon). DPI reduces the basal production to $25 \pm 15 \text{ nM}$.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Coincubation with SOD further enhances the maximum H₂O₂ production from 219 ± 22 nM to 260 ± 15 nM (Fig.2).

Topological fluorescence analysis of H₂O₂-production by platelets

Since the level of ROS in the supernatant is not able to reflect a possible local enrichment of ROS, we tried to identify ROS topologically by fluorescence microscopy. PMA-stimulated neutrophils showed very bright fluorescent dots, likely phagolysosomes (Fig. 3A). If platelets were stimulated with PMA, we found a very weak fluorescence signal surrounding some aggregated platelets (Fig. 3B). At bacteria-platelet-binding sites, no particular H₂O₂ signal was detectable.

No colocalization of H₂O₂ - production and killing of bacteria

Since fluorescence detection was unable to demonstrate any locally restricted ROS-synthesis in platelets, we further tried to detect H₂O₂-release by ceriumperhydroxide precipitation as visualized by electron microscopy.

As reported by Repine et al. [38], in PMA-stimulated neutrophils the external surface of the plasma membrane was coated with a thick layer of electron dense material representing this precipitation. To assure about the validity of the H₂O₂ detection by the CeCl₃ method, we added catalase to the activated neutrophils. Catalase abolishes the released H₂O₂. Following addition of catalase, PMA-activated neutrophils showed no ceriumperhydroxide crystals on the plasma membrane. Unstimulated neutrophils displayed ceriumperhydroxide crystals only at a few sites.

In coincubation experiments of PMA-stimulated neutrophils with *B. subtilis*, most bacteria were phagocytosed. Within vacuoles of some neutrophils, ceriumperhydroxide crystals are seen, which indicates the local synthesis of H₂O₂ (Fig. 4 A-D).

In contrast to neutrophils, platelets never showed any ceriumperhydroxide crystals at the plasma membrane, regardless of any stimulation. Although a lot of viable and dead *B. subtilis* were enclosed in platelet aggregates or in platelets themselves, no electron dense material was detectable at binding sites of *B. subtilis*, suggesting that no H₂O₂ was produced at these sites (Fig.4 E-H).

Promoting platelet ROS-generation does not lead to higher killing rates

B. subtilis is highly susceptible to thrombin-stimulated platelets with killing rates to nearly 100 % within 10 min. We compared these killing rates with those achieved following PMA-stimulation of platelets. PMA does not yield any significant killing effect within 10 min

1
2
3 (13 ± 6 % versus baseline 8 ± 3 %, p>0.05, Wilcoxon). After 20, 30 and 45 min incubation
4 time, the PMA-stimulated platelets only reached a moderate killing up to 50 ± 20 %, which
5 was significantly higher than the control but did not reach the killing efficacy of stimulation
6 with thrombin (Fig. 5, p<0.001, Wilcoxon, n=5).
7
8
9

10 11 **Inhibition of O₂⁻ does influence killing rates partially**

12 To determine if the killing is ROS dependent, we also inhibited the superoxide generating
13 NAD(P)H-oxidase by preincubation of cells with DPI. When thrombin was used as a
14 stimulator, the preincubation with DPI (0.1mM) leads to a tendency of decreased killing of
15 *B. subtilis* within 10 min (80 ± 20 % versus 92 ± 5 %, p= 0.2, Wilcoxon) and was
16 significantly decreased after 20 min (68 ± 24 % versus 87 ± 10 %, p= 0.009, Wilcoxon) and
17 after 45 min (74 ± 20 % versus 95 ± 6 %, p= 0.0006, Wilcoxon, n=5).
18
19

20 If DPI-preincubated platelets are stimulated with PMA, the rate of dead bacteria vary slightly
21 from 13 ± 6 % (PMA) to 21 ± 7 % (DPI/PMA) after 10 min (n=5). After 20 and 30 min
22 incubation, there was the same killing rate with or without DPI. Only after 45 min the killing
23 rate decreased significantly from 50 ± 20 % (PMA) to 40 ± 16 % (DPI/PMA; p= 0.03,
24 Wilcoxon, n= 5).
25
26
27
28
29
30
31
32
33

34 **H₂O₂-addition at platelet synthesis levels is not bactericidal to *B. subtilis***

35 To determine at which H₂O₂-concentrations *B. subtilis* is killed, we established a dose-
36 response relationship in the range from 0.05 to 50 mM H₂O₂. Since *B. subtilis* is catalase
37 positive [39], it is relatively resistant against ROS. At concentrations up to 5 mM we observed
38 no bactericidal effect on *B. subtilis* (11 ± 5 % versus 11 ± 3 % of dead bacteria in controls).
39 At concentrations of 50 mM H₂O₂ we observed only 25 ± 1 % killed bacteria (n=3). With a
40 synthesis of 1 μM H₂O₂ in 10 min, platelet concentrates only produce less than 1/10⁵ of H₂O₂
41 that would be needed for effective killing of this bacteria.
42
43
44
45
46
47
48
49
50

51 **Killing rates are dependent on addition of plasma**

52 Blood plasma contains many adhesive proteins, which could enhance the binding of bacteria
53 to platelets and thereby change the rate of killing. To determine the role of plasma
54 components in the bactericidal mechanism of platelets, we used gel-filtered platelets with
55 addition of increasing plasma portions.
56
57
58

59 Thrombin-stimulated platelets in buffer killed only 22 ± 22 % of the added bacteria, which
60 was significantly less than the maximum control in plasma (p<0.001, Wilcoxon, n=3). But

1
2
3 already a proportion of 20 % plasma completely regains the bactericidal effect (100 %). If the
4 plasma was heat-inactivated, no killing was observed (8 ± 3 % versus baseline 11.1 ± 2.8 %).
5
6
7

8 **Plasma but not Serum is bactericidal after addition of thrombin**

9
10 Because plasma seemed to be crucial for yielding high killing rates of *B. subtilis*, we tested if
11 plasma can kill these bacteria without the addition of platelets.
12

13 Plasma without platelets showed no significant killing (19 ± 4 %). The addition of thrombin
14 to plasma resulted in a high killing rate of 84 ± 17 %, which was still significantly below the
15 maximum control shown in fig.5 ($p=0.0011$, Wilcoxon). **The inhibition of thrombin activity
16 by hirudin completely aborted bactericidal effects, also the incubation of *B. subtilis* with
17 thrombin alone, without addition of plasma, did not show any significant killing (17 ± 8 %).**
18
19

20
21 To exclude complement or antibody effects in the killing assay, we also tested the bactericidal
22 effects of serum. But in the presence of serum there was no killing observed with (18 ± 7 %)
23 or without the addition of thrombin (19 ± 6 %).
24
25
26
27
28

29 **Plasma protein fraction > 100 kDa mediates the high killing rates**

30
31 To determine the plasma component, which cause the high killing rates, we fractionated the
32 plasma proteins with two filters in the MW ranges > 10 kDa, < 10 kDa, > 100 kDa and
33 < 100 kDa and tested the killing rates after addition of these fractions to gel-filtered platelets.
34
35 It was determined, that the fraction > 100 kDa was responsible for a killing as high as
36 91 ± 8 %. The effects of the fractions > 100 kDa and > 10 kDa were not significantly different
37 from killing rates in normal plasma (max-control), which reached 95 ± 5 % ($p= 0.34$,
38 Wilcoxon). In contrast, the fractions < 100 kDa showed a decreased killing of 33 ± 8 % and
39 the fraction < 10 kDa reached only 19 ± 8 % (Fig. 6).
40
41
42
43
44
45
46
47

48 **Thrombin interaction with platelet receptors is not responsible for killing *B. subtilis***

49
50 In our experiments thrombin was always crucial for killing of *B. subtilis*. Therefore we
51 studied which effect of thrombin was responsible for the observed killing. Thrombin activates
52 human platelets via the protease activating receptors (PAR) 1 and 4. We dissected these
53 effects by using the synthetic thrombin receptor agonists SFLLRN (SF) for activating the
54 platelet PAR 1 and GYPGKF (GYP) for activating PAR 4. SF reached a maximum killing of
55 39 ± 19 %, whereas GYP achieved a maximum killing of 34 ± 20 %. Both activators together
56 yielded a killing rate of 41 ± 20 %. To mimic the proteolytical function of thrombin, we also
57 used trypsin in killing experiments. Trypsin reached a significant higher killing rate compared
58
59
60

1
2
3 to GYP or SF with a killing of $56 \pm 16 \%$, but did not achieve the killing rate that was
4
5 observed upon thrombin stimulation ($83 \pm 19 \%$).
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Discussion

While the critical role of platelets in haemostasis, thrombosis and inflammation is clearly identified, their contribution to the innate host defense has received much less attention though the bactericidal properties of blood and platelets have been described for the first time as early as one century ago [11].

In analogy to leukocytes, 3 basic bactericidal mechanisms are thinkable to exist in platelets:

1. storage and processing of bactericidal proteins, 2. phagocytosis and 3. synthesis of reactive oxygen species (ROS).

1. Storage and processing of bactericidal proteins

In 1960 Hirsch et al. [40] demonstrated bactericidal activities of rabbit serum that are not present prior to clotting. He noticed that plasma regains its bactericidal effect after addition of platelets but not after addition of leukocytes or erythrocytes. Investigations on that subject were intensified in the 1970's. Donaldson et al. [41-43] isolated β -lysin as one bactericidal protein, which is stored in rabbit platelets at high concentrations but also occurs to a lower extend in human platelets. Since then several authors focussed on isolating the supposed bactericidal proteins derived from platelets. Nachman et al. [4;44] and the group leaded by Yeaman [45-48] isolated and characterized platelet microbicidal proteins in rabbits. Later on Krijgsveld et al. described analogous bactericidal proteins in human platelets that are released upon thrombin stimulation [13]. Surprisingly, these proteins differ from not bactericidal proteins by a proteolytical truncation of only 2 amino acids. The possibility exist, that thrombin or other extracellular proteases cleave a precursor protein, which contributes to the generation of bactericidal proteins [2]. According to these findings, Tang et al. [14] could identify more bactericidal proteins in human platelets, but two of them are only present in stimulated platelets.

In our model of killing of *B. subtilis*, however, several lines of evidence militate against a main role of bactericidal proteins. Platelet releasates, in our hands, only exert moderate killing effects [9], and we observed a massive killing of bacteria with thrombin-stimulated platelets at about 100fold lower platelet concentrations in comparison to Krijgsveld et al.[13]. Moreover, in earlier investigations we could show, that even completely degranulated platelets have bactericidal capacity [9]. A possible explanation for these conflicting data on bactericidal activity of platelet releasates is presented by Tang et al. [14], who supposed an inhibiting effect of sodium phosphate which is used in most buffer systems.

2. Phagocytosis

Lewis et al. [49] demonstrated for the first time that platelets really phagocytose small particles ($<0.1 \mu\text{m}$), which means that lysosomes fuse with the phagosome and no luminal continuity exists to the outer space. Latex particles were endocytosed through the OCS and reached the cytoplasm in small vesicles. But this way of ingestion is doubtful for bacteria with its much larger size ($2 \mu\text{m}$). Resuming the works of decades, Clawson found no evidences for a real phagocytosis of bacteria [3]. He observed that stimulated platelets recruit other platelets and the growing platelet aggregate surrounds initially adhered bacteria. There they are well separated from the surrounding media and usually appear within interspaces. But really engulfed bacteria are rarely to be seen in platelets [50]. Although granule secretion at platelet-bacteria binding sites was observed, no killing of bacteria was described [3]. That is contrary to our investigations. Youssefian et al. [51] postulated an engulfment of *Staphylococcus aureus* in platelets, which is enhanced after stimulation. But he did not point out that killing occurs after engulfing. From White's updated point of view, bacteria are too big to be actively and completely enclosed within platelets. Therefore platelets may just cover bacteria as "covercytes" to separate this foreign material from the blood stream in vivo [16].

3. Synthesis of reactive oxygen species

After phagocytosis by neutrophils, ROS play an important role in the definitive killing of pathogens. Several clues exist that also platelet-derived ROS could be engaged in host defense: ROS-dependent cytotoxic effects were described in the platelet-mediated killing of helminths [52], ruffled platelet membranes were observed at bacteria binding sites [9], and a decreased killing of bacteria was observed to occur in the presence of antioxidants (own unpublished data). Thus we tried to establish the role of ROS in killing *B. subtilis* by platelets. The term ROS contains several molecular species with different properties. The key role has superoxide anion (O_2^-) as the first molecule in the complete reaction chain. Being unstable, it is converted to peroxynitrite or by superoxide dismutase (SOD) to hydrogen peroxide (H_2O_2). H_2O_2 itself is strongly bactericidal and can be further converted into other bactericidal oxygen species. In 1977, Marcus et al. [53] found superoxide (O_2^-) production and in 1982 Finazzi-Agro et al. [54] could detect hydrogen peroxide (H_2O_2) release from platelets. First hints that platelet-derived ROS have cytotoxic effects was given by Joseph et al. in IgE-mediated killing of helminths [52;55]. This hypothesis is aided by our findings of ruffled membranes at platelet-bacteria binding sites which suggested similarities to ROS generating neutrophils [27] and osteoclasts [28]. In these cells, ruffled membranes are generated by actin

1
2
3 polymerization and become sites of assembly of the NAD(P)H-oxidase complex. In this way,
4 neutrophils and osteoclasts produce locally restricted large quantities of ROS to kill bacteria
5 or to remodel the bone matrix. In addition to ruffled membranes, we observed a decreased
6 killing rate by addition of the antioxidant vitamin E (α -tocopherol) in earlier investigations in
7 our laboratory (unpublished data).
8

9
10 Based on these reports and observations, we assumed a possible role for platelet-derived ROS
11 in our bactericidal model. We focussed in our experiments on detecting the release of O_2^- and
12 H_2O_2 quantitatively as well as topologically, and we studied the influence of stimulation and
13 inhibition of ROS-synthesis on the resulting killing rates.
14

15
16 *B. subtilis* is highly susceptible to the killing abilities of thrombin-stimulated platelets. It is a
17 Gram- and catalase-positive bacterium, which has 3 catalases [39], and it should be well
18 protected against the cytotoxic effects of H_2O_2 . In our experiments we detected that one
19 platelet does produce about 1500 times less superoxide and 4000 times less H_2O_2 compared to
20 one neutrophil. Although the concentration of platelets in native blood is 30 times higher and
21 under our experimental conditions even 100- 500fold higher than the physiological
22 concentration of neutrophils, the detected ROS release does not reach bactericidal dimensions
23 for *B. subtilis* at all. Consistent with your observation that 50 mM H_2O_2 kills 25 % of
24 *B. subtilis* within 10 min, Murphy et al. demonstrated that 10 mM H_2O_2 is enough to kill
25 almost all *B. subtilis* by a longer incubation time of 1 h [56].
26
27
28
29
30
31
32
33
34
35
36
37

38
39 The detection of very low levels of ROS with subsequent high standard deviations and the
40 disappointing weak reaction to stimulators led us to the assumption, that aggregated platelets
41 can not release all generated ROS into the supernatant. In this way, freshly synthesized ROS
42 inside a platelet aggregate will be converted before it will be detected in the supernatant. That
43 might explain the low ROS detection when strong aggregating agents like thrombin were
44 used.
45
46
47
48

49
50 Another critical factor in the ROS assay is that the isolation process prestimulates platelets in
51 a donor-dependent fashion, so that it is difficult to further increase ROS production with
52 stimulators. Low amounts and prestimulated, aggregated platelets hamper the exact
53 quantification of ROS release. Another delicate point is that platelet concentrates are not
54 totally free of neutrophils. To assure about the cellular source of ROS (neutrophils or
55 platelets), we used a direct local detection of ROS in addition to the cytochrom C or
56 phenolred/peroxidase assays. Both electron and fluorescence microscopy revealed that no
57 locally restricted ROS synthesis could be found at platelet-bacteria binding sites. In contrast
58
59
60

1
2
3 to that, neutrophils show a strong ROS production as visualized with both microscopical
4 methods, whereas in platelets nearly no detection of H₂O₂ is possible.

5
6 Finally we investigated and compared the killing effects of PMA- and thrombin-stimulated
7 platelets to determine the role of ROS in killing *B. subtilis*. Stimulation by PMA yields only a
8 moderate killing rate after prolonged time compared to platelet stimulation by thrombin,
9 which kill with high efficiency within a few minutes. Furthermore we preincubated platelets
10 with DPI, an unspecific inhibitor of NAD(P)H-oxidase in neutrophils. DPI preincubated
11 platelets do change their thrombin-dependent killing of bacteria partially. Hence neither PMA
12 did increase the killing of *B. subtilis* nor did DPI inhibit the enormous thrombin-mediated
13 killing clearly.
14
15

16
17 So until now, neither bactericidal peptides nor phagocytosis or ROS release can explain the
18 mechanism of platelet-mediated bactericidal action, and we have to conclude that the platelets
19 obviously have learned not enough from their big brothers, the granulocytes. But what
20 establishes their bactericidal activity, which is clearly observed both *in vitro* and *in vivo*?
21
22 Platelets might have found their own way, to participate in host defense.
23
24
25
26
27
28
29
30
31

32 **4. Role of Thrombin and Plasma Proteins**

33 In all experiments it was remarkable that the presence of plasma as well as a stimulation by
34 thrombin was essential to kill *B. subtilis*. Gel-filtered and thrombin-stimulated platelets
35 showed no killing effects until at least a portion of 20 % plasma was added. In contrast, heat-
36 inactivated plasma, a plasma protein fraction < 100 kDa, serum or thrombin alone offered no
37 killing potential. Therefore complement or antibody action in that killing can be excluded,
38 because these components are also present in the serum.
39
40
41
42

43 Furthermore, the action of thrombin was mimicked by the synthetic thrombin receptor
44 agonists SFLLRN or GYPGKF, which stimulated the platelets without having any proteolytic
45 effects [32;33]. Although the platelets were activated and degranulated, no remarkable killing
46 of *B. subtilis* occurred.
47
48
49
50

51 In conclusion, the observed bactericidal effects do not seem to be mainly due to an active
52 contribution of platelets, like bactericidal peptides, the production of ROS or phagocytosis.
53 The present work rather suggests that platelets contribute to the innate host defense by
54 providing a catalytical surface for synthesis of thrombin. Thrombin was always added in our
55 *in-vitro* experiments, but can be generated *in vivo* only in close contact to the platelet surface.
56
57 **Inhibition of thrombin by hirudin completely abolishes all bactericidal activity of plasma in**
58 **our experiments.** In the presence of a heat-instable plasma protein with a MW > 100 kDa, the
59
60

1
2
3 protease thrombin seems to generate a bactericidal compound, which is responsible for the
4 observed killing.
5

6
7 Distinct evidence from animal and clinical studies exist, that platelets are effectively engaged
8 in innate host defense. Several *in vitro* and animal studies have shown that the susceptibility
9 of bacteria to platelet-mediated defense mechanisms influences the induction and progression
10 of endovascular infections [57-60]. For example, Sullam et al. tested the effects of an induced
11 thrombocytopenia in rabbits on heart valve endocarditis after infection with *Streptococcus*
12 *sanguis*. Compared to controls, thrombocytopenic rabbits had higher densities of streptococci
13 per valve [57].
14

15
16 In several clinical studies it was described, that thrombocytopenia in man is also accompanied
17 by higher morbidity and mortality. An increased incidence and severity of lobar pneumonia in
18 elderly individuals with thrombocytopenia was described [61], thrombocytopenia was found
19 to be a significant predictor of mortality in pneumococcal meningitis [62], and in liver
20 transplant recipients thrombocytopenia is an independent and significant predictor associated
21 with increased infection and related morbidity and mortality [63].
22

23
24 However, the less pathogenic bacteria species *B. subtilis* and *E. coli* were steadily killed in
25 our experiments, whereas *S. aureus* could not be killed. Thus, the effect of platelet-mediated
26 antibacterial defense mechanisms seems to be limited to less pathogenic species, or vice
27 versa, the ability to escape from the platelet-mediated defense makes bacteria much more
28 pathogenic.
29

30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 **Acknowledgements** 45

46
47
48 This work was supported by the Deutsche Forschungsgemeinschaft (GRK 288).
49

50
51
52 We want to thank Dr. P. Schlenke and Dr. S. Görg from the Institute of Immunology and
53 Transfusion Medicine at the University of Lübeck for providing us with platelet concentrates
54 and buffy coats. The excellent technical assistance by Tine Asmus, Kerstin Fibelkorn and
55 Jutta Endler is gratefully acknowledged.
56
57

58
59
60 The authors have declared no conflict of interest.

References

- [1] Klinger MH, Jelkmann W: Role of blood platelets in infection and inflammation. *J Interferon Cytokine Res* 2002, 22, 913-922.
- [2] Yeaman MR, Bayer AS: Antimicrobial host defense; in Michelson AD (ed): *Platelets*. London, Academic Press, 2002, pp 469-482.
- [3] Clawson CC: Platelets in bactericidal infections; in Joseph M (ed): *Immunopatharmacology of platelets*. London, Academic Press, 1995, pp 83-124.
- [4] Nachman RL, Weksler B: The platelet as an inflammatory cell. *Ann N Y Acad Sci* 1972, 201, 131-137.
- [5] Simonet M, Triadou P, Frehel C, Morel-Kopp MC, Kaplan C, Berche P: Human platelet aggregation by *Yersinia pseudotuberculosis* is mediated by invasins. *Infect Immun* 1992, 60, 366-373.
- [6] Alugupalli KR, Michelson AD, Barnard MR, Robbins D, Coburn J, Baker EK, Ginsberg MH, Schwan TG, Leong JM: Platelet activation by a relapsing fever spirochaete results in enhanced bacterium-platelet interaction via integrin α IIb β 3 activation. *Mol Microbiol* 2001, 39, 330-340.
- [7] Herzberg MC, Gong K: Platelets and bacterial infections; in Gresele P, Page C, Fuster V, Vermynen J (eds): *Platelets in thrombotic and non-thrombotic disorders*. Cambridge, Cambridge - University Press, 2002, pp 783-805.
- [8] Dankert J, van Der WJ, Zaat SA, Joldersma W, Klein D, Hess J: Involvement of bactericidal factors from thrombin-stimulated platelets in clearance of adherent viridans streptococci in experimental infective endocarditis. *Infect Immun* 1995, 63, 663-671.
- [9] Klinger M, Ulbricht T: Participation of human blood platelets in antimicrobial host defense. *Transfus Med Hemother* 2003, 30, 57-62.
- [10] Clawson CC, White JG, Herzberg MC: Platelet interaction with bacteria. VI. contrasting the role of fibrinogen and fibronectin. *Am J Hematol* 1980, 9, 43-53.
- [11] Fodor j: Die Fähigkeit des Blutes Bakterien zu vernichten. *Dtsch Med Wochenschau* 1887, 13, 745-747.
- [12] Yeaman MR, Tang YQ, Shen AJ, Bayer AS, Selsted ME: Purification and in vitro activities of rabbit platelet microbicidal proteins. *Infect Immun* 1997, 65, 1023-1031.

- 1
2
3 [13] Krijgsveld J, Zaat SA, Meeldijk J, van Veelen PA, Fang G, Poolman B, Brandt E,
4 Ehlert JE, Kuijpers AJ, Engbers GH, Feijen J, Dankert J: Thrombocidins, microbicidal
5 proteins from human blood platelets, are C-terminal deletion products of CXC
6 chemokines. *J Biol Chem* 2000, *275*, 20374-20381.
7
8
9 [14] Tang YQ, Yeaman MR, Selsted ME: Antimicrobial peptides from human platelets.
10 *Infect Immun* 2002, *70*, 6524-6533.
11
12 [15] Meseguer J, Esteban MA, Rodriguez A: Are thrombocytes and platelets true
13 phagocytes? *Microsc Res Tech* 2002, *57*, 491-497.
14
15 [16] White JG: Platelets are coverocytes, not phagocytes: uptake of bacteria involves
16 channels of the open canalicular system. *Platelets* 2005, *16*, 121-131.
17
18 [17] Krotz F, Sohn HY, Pohl U: Reactive oxygen species: players in the platelet game.
19 *Arterioscler Thromb Vasc Biol* 2004, *24*, 1988-1996.
20
21 [18] Maresca M, Colao C, Leoncini G: Generation of hydrogen peroxide in resting and
22 activated platelets. *Cell Biochem Funct* 1992, *10*, 79-85.
23
24 [19] Krotz F, Sohn HY, Gloe T, Zahler S, Riexinger T, Schiele TM, Becker BF, Theisen K,
25 Klaus V, Pohl U: NAD(P)H oxidase-dependent platelet superoxide anion release
26 increases platelet recruitment. *Blood* 2002, *100*, 917-924.
27
28 [20] Wachowicz B, Olas B, Zbikowska HM, Buczynski A: Generation of reactive oxygen
29 species in blood platelets. *Platelets* 2002, *13*, 175-182.
30
31 [21] Leo R, Pratico D, Iuliano L, Pulcinelli FM, Ghiselli A, Pignatelli P, Colavita AR,
32 FitzGerald GA, Violi F: Platelet activation by superoxide anion and hydroxyl radicals
33 intrinsically generated by platelets that had undergone anoxia and then reoxygenated.
34 *Circulation* 1997, *95*, 885-891.
35
36 [22] Caccese D, Pratico D, Ghiselli A, Natoli S, Pignatelli P, Sanguigni V, Iuliano L, Violi
37 F: Superoxide anion and hydroxyl radical release by collagen-induced platelet
38 aggregation--role of arachidonic acid metabolism. *Thromb Haemost* 2000, *83*, 485-
39 490.
40
41 [23] Pignatelli P, Pulcinelli FM, Lenti L, Gazzaniga PP, Violi F: Hydrogen peroxide is
42 involved in collagen-induced platelet activation. *Blood* 1998, *91*, 484-490.
43
44 [24] Sanner BM, Meder U, Zidek W, Tepel M: Effects of glucocorticoids on generation of
45 reactive oxygen species in platelets. *Steroids* 2002, *67*, 715-719.
46
47 [25] Babior BM, Kipnes RS, Curnutte JT: Biological defense mechanisms. The production
48 by leukocytes of superoxide, a potential bactericidal agent. *J Clin Invest* 1973, *52*,
49 741-744.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 [26] Jandl RC, ndre-Schwartz J, Borges-DuBois L, Kipnes RS, McMurrich BJ, Babior BM:
4 Termination of the respiratory burst in human neutrophils. *J Clin Invest* 1978, *61*,
5 1176-1185.
6
7
8 [27] Robinson JM, Badwey JA: The NADPH oxidase complex of phagocytic leukocytes: a
9 biochemical and cytochemical view. *Histochem Cell Biol* 1995, *103*, 163-180.
10
11
12 [28] Key LL, Jr., Wolf WC, Gundberg CM, Ries WL: Superoxide and bone resorption.
13 *Bone* 1994, *15*, 431-436.
14
15
16 [29] Vu TK, Hung DT, Wheaton VI, Coughlin SR: Molecular cloning of a functional
17 thrombin receptor reveals a novel proteolytic mechanism of receptor activation. *Cell*
18 1991, *64*, 1057-1068.
19
20
21 [30] Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, Gilbert T, Davie
22 EW, Foster DC: Cloning and characterization of human protease-activated receptor 4.
23 *Proc Natl Acad Sci USA* 1998, *95*, 6642-6646.
24
25
26 [31] Blomback B, Blomback M, Hessel B, Iwanaga S: Structure of N-terminal fragments
27 of fibrinogen and specificity of thrombin. *Nature* 1967, *215*, 1445-1448.
28
29
30 [32] Dohlman HG, Thorner J, Caron MG, Lefkowitz RJ: Model systems for the study of
31 seven-transmembrane-segment receptors. *Annu Rev Biochem* 1991, *60*, 653-688.
32
33
34 [33] Hollenberg MD, Compton SJ: International Union of Pharmacology. XXVIII.
35 Proteinase-activated receptors. *Pharmacol Rev* 2002, *54*, 203-217.
36
37
38 [34] Cabanis A, Gressier B, Lebegue S, Brunet C, Dine T, Luyckx M, Cazin M, Cazin JC:
39 A rapid density gradient technique for separating polymorphonuclear granulocytes.
40 *APMIS* 1994, *102*, 119-121.
41
42
43 [35] Timmons S, Hawiger J: Isolation of Platelets; in *Methods of Enzymology* Vol 169. San
44 Diego, Academic Press, 1989, pp 11-21.
45
46
47 [36] Briggs RT, Drath DB, Karnovsky ML, Karnovsky MJ: Localization of NADH oxidase
48 on the surface of human polymorphonuclear leukocytes by a new cytochemical
49 method. *J Cell Biol* 1975, *67*, 566-586.
50
51
52 [37] Telek G, Scoazec JY, Chariot J, Ducroc R, Feldmann G, Roz C: Cerium-based
53 histochemical demonstration of oxidative stress in taurocholate-induced acute
54 pancreatitis in rats. A confocal laser scanning microscopic study. *J Histochem*
55 *Cytochem* 1999, *47*, 1201-1212.
56
57
58 [38] Repine JE, White JG, Clawson CC, Holmes BM: The influence of phorbol myristate
59 acetate on oxygen consumption by polymorphonuclear leukocytes. *J Lab Clin Med*
60 1974, *83*, 911-920.

- 1
2
3 [39] Loewen PC, Switala J: Multiple catalases in *Bacillus subtilis*. *J Bacteriol* 1987, *169*,
4 3601-3607.
5
6
7 [40] Hirsch JG: Comparative bactericidal activities of blood serum and plasma serum. *J*
8 *Exp Med* 1960, *112*, 15-22.
9
10
11 [41] Donaldson DM, Tew JG: beta-Lysin of platelet origin. *Bacteriol Rev* 1977, *41*, 501-
12 513.
13
14
15 [42] Roberts RR, Tew JG, Donaldson DM: Release of beta-lysin from platelets caused by
16 antigen-antibody complexes, purified enzymes, and platelet-aggregating substances.
17 *Infect Immun* 1977, *15*, 485-490.
18
19
20 [43] Tew JG, Roberts RR, Donaldson DM: Release of beta-lysin from platelets by
21 thrombin and by a factor produced in heparinized blood. *Infect Immun* 1974, *9*, 179-
22 186.
23
24
25 [44] Weksler BB, Nachman RL: Rabbit platelet bactericidal protein. *J Exp Med* 1971, *134*,
26 1114-1130.
27
28
29 [45] Yeaman MR, Tang YQ, Shen AJ, Bayer AS, Selsted ME: Purification and in vitro
30 activities of rabbit platelet microbicidal proteins. *Infect Immun* 1997, *65*, 1023-1031.
31
32
33 [46] Yeaman MR, Puentes SM, Norman DC, Bayer AS: Partial characterization and
34 staphylocidal activity of thrombin-induced platelet microbicidal protein. *Infect Immun*
35 1992, *60*, 1202-1209.
36
37
38 [47] Yeaman MR, Norman DC, Bayer AS: Platelet microbicidal protein enhances
39 antibiotic-induced killing of and postantibiotic effect in *Staphylococcus aureus*.
40 *Antimicrob Agents Chemother* 1992, *36*, 1665-1670.
41
42
43 [48] Yeaman MR, Norman DC, Bayer AS: *Staphylococcus aureus* susceptibility to
44 thrombin-induced platelet microbicidal protein is independent of platelet adherence
45 and aggregation in vitro. *Infect Immun* 1992, *60*, 2368-2374.
46
47
48 [49] Lewis JC, Maldonado JE, Mann KG: Phagocytosis in human platelets: localization of
49 acid phosphatase-positive phagosomes following latex uptake. *Blood* 1976, *47*, 833-
50 840.
51
52
53 [50] Clawson CC, Repine JE: Proceedings: Products of platelet aggregation and release as
54 a chemotactic factor for human leucocytes. *Thromb Diath Haemorrh* 1975, *34*, 603.
55
56
57 [51] Youssefian T, Drouin A, Masse JM, Guichard J, Cramer EM: Host defense role of
58 platelets: engulfment of HIV and *Staphylococcus aureus* occurs in a specific
59 subcellular compartment and is enhanced by platelet activation. *Blood* 2002, *99*, 4021-
60 4029.

- 1
2
3 [52] Joseph M, Auriault C, Capron M, Ameisen JC, Pancre V, Torpier G, Kusnierz JP,
4 Ovlaque G, Capron A: IgE-dependent platelet cytotoxicity against helminths. *Adv Exp*
5 *Med Biol* 1985, *184*, 23-33.
6
7
8 [53] Marcus AJ, Silk ST, Safier LB, Ullman HL: Superoxide production and reducing
9 activity in human platelets. *J Clin Invest* 1977, *59*, 149-158.
10
11 [54] Finazzi-Agro A, Menichelli A, Persiani M, Biancini G, Del PD: Hydrogen peroxide
12 release from human blood platelets. *Biochim Biophys Acta* 1982, *718*, 21-25.
13
14 [55] Tran A, Vanhee D, Capron A, Vorng H, Braquet P, Joseph M: Separate induction of
15 human blood platelet aggregation or cytotoxicity by different concentrations of PAF-
16 acether and thrombin. *Agents Actions* 1992, *36*, 39-43.
17
18 [56] Murphy P, Dowds BC, McConnell DJ, Devine KM: Oxidative stress and growth
19 temperature in *Bacillus subtilis*. *J Bacteriol* 1987, *169*, 5766-5770.
20
21 [57] Sullam PM, Frank U, Yeaman MR, Tauber MG, Bayer AS, Chambers HF: Effect of
22 thrombocytopenia on the early course of streptococcal endocarditis. *J Infect Dis* 1993,
23 *168*, 910-914.
24
25 [58] Bayer AS, Cheng D, Yeaman MR, Corey GR, McClelland RS, Harrel LJ, Fowler VG,
26 Jr.: In vitro resistance to thrombin-induced platelet microbicidal protein among
27 clinical bacteremic isolates of *Staphylococcus aureus* correlates with an endovascular
28 infectious source. *Antimicrob Agents Chemother* 1998, *42*, 3169-3172.
29
30 [59] Mercier RC, Rybak MJ, Bayer AS, Yeaman MR: Influence of platelets and platelet
31 microbicidal protein susceptibility on the fate of *Staphylococcus aureus* in an in vitro
32 model of infective endocarditis. *Infect Immun* 2000, *68*, 4699-4705.
33
34 [60] Kupferwasser LI, Yeaman MR, Shapiro SM, Nast CC, Bayer AS: In vitro
35 susceptibility to thrombin-induced platelet microbicidal protein is associated with
36 reduced disease progression and complication rates in experimental *Staphylococcus*
37 *aureus* endocarditis: microbiological, histopathologic, and echocardiographic analyses.
38 *Circulation* 2002, *105*, 746-752.
39
40 [61] Feldman C, Kallenbach JM, Levy H, Thorburn JR, Hurwitz MD, Koornhof HJ:
41 Comparison of bacteraemic community-acquired lobar pneumonia due to
42 *Streptococcus pneumoniae* and *Klebsiella pneumoniae* in an intensive care unit.
43 *Respiration* 1991, *58*, 265-270.
44
45 [62] Kirkpatrick B, Reeves DS, MacGowan AP: A review of the clinical presentation,
46 laboratory features, antimicrobial therapy and outcome of 77 episodes of
47 pneumococcal meningitis occurring in children and adults. *J Infect* 1994, *29*, 171-182.
48
49 [63] Chang FY, Singh N, Gayowski T, Wagener MM, Mietzner SM, Stout JE, Marino IR:
50 Thrombocytopenia in liver transplant recipients: predictors, impact on fungal
51 infections, and role of endogenous thrombopoietin. *Transplantation* 2000, *69*, 70-75.
52
53
54
55
56
57
58
59
60

Figure legends

Fig. 1

Release of superoxide anion by platelets (left y axis) and neutrophils (right y axis) following stimulation with PMA and inhibition with DPI. Whereas neutrophils clearly respond to both stimulation and inhibition, the platelets did not react significantly. Calculated onto a per cell basis, a maximum stimulation with PMA induces one neutrophil to release appr. 1500-fold more O_2^- than one platelet. Thus, release of superoxide anion will not substantially contribute to bactericidal activity of platelets.

Fig. 2

Release of hydrogen peroxide by platelets (left y axis) and neutrophils (right y axis) following stimulation with PMA or inhibition with DPI. Both cells significantly react on the maximum stimulus (Asterisks; $p < 0.05$; Wilcoxon), but platelets fail to further enhance their hydrogen peroxide release after addition of SOD. Calculated onto a per cell basis, a maximum stimulation with PMA induces one neutrophil to release appr. 4000-fold more H_2O_2 than one platelet. Thus, release of hydrogen peroxide will not substantially contribute to bactericidal activity of platelets.

Fig. 3

Topological fluorescence analysis of hydrogen peroxide release following PMA stimulation of neutrophils (A) and platelets (B). In neutrophils, the circumferentially located phagolysosomes release a strong signal, but the fluorescence intensity produced by aggregated platelets is very weak and does not show local enrichment of the signal, thus not supporting a role of hydrogen peroxide in the killing of bacteria by platelets.

Bars: 5 μm

1
2
3
4
5
6 Fig. 4 A - D
7

8 Electron microscopical detection of neutrophil hydrogen peroxide release by precipitation of
9 cerium perhydroxide. Stimulation of neutrophils with PMA induces precipitation on the outer
10 cell membran and also on the inner aspect of vacuoles (arrows in A). Addition of catalase
11 totally abolishes the precipitation, thereby confirming the specificity of the reaction (B).
12
13 Unstimulated neutrophils display crystals only at a few sites (C). At higher magnification,
14 precipitation (arrow) can be detected close to ingested bacteria (Bs).
15
16
17
18
19
20
21

22 Bars: 1 μ m
23
24
25
26

27 Fig. 4 E - H
28

29 Electron microscopical detection of platelet hydrogen peroxide release by precipitation of
30 cerium perhydroxide. Neither stimulation with PMA (A), nor stimulation in the presence of
31 catalase (B), control platelets (C) or ingestion of bacteria (D; Bs) lead to any precipitation of
32 cerium perhydroxide. Thus, the assumption of a local enrichment of reactive oxygen species
33 is not supported.
34
35
36
37
38
39

40 Bars: 1 μ m
41
42
43
44
45

46 Fig. 5
47

48 Killing of bacteria by stimulated platelets. Whereas stimulation of platelets with thrombin
49 leads to nearly complete killing already after 10 min, stimulation with PMA only induces
50 moderate killing rates after 20 and more min.
51
52


53 Asterisks: Significantly higher killing rates compared to the baseline value ($p < 0.01$;

54 Wilcoxon)
55
56
57
58
59
60


1
2
3 Fig. 6
4

5 Killing of bacteria by thrombin-stimulated platelets is dependent from the presence of blood
6 plasma components. Gel-filtered platelets resuspended in buffer exert a comparable low
7
8 killing activity like platelets in serum or platelets in plasma without high molecular weight
9
10 proteins. To achieve a maximum of killing, both the plasma protein fraction above 100 kD
11
12 and the activity of thrombin are required.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


For Peer Review



Zander & Klinger: Fig. 1
120x76mm (600 x 600 DPI)




Zander & Klinger: Fig. 2
120x80mm (600 x 600 DPI)




Zander & Klinger: Fig. 3
80x46mm (300 x 300 DPI)


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Zander & Klinger: Fig. 4a-d
160x226mm (300 x 300 DPI)



Zander & KLinger: Fig. 4e-h
160x226mm (300 x 300 DPI)



Zander & Klinger: Fig. 5
120x80mm (600 x 600 DPI)



Zander & Klinger: Fig. 6
120x90mm (600 x 600 DPI)